Cargando…
Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
BACKGROUND: The impact of nonalcoholic fatty liver disease (NAFLD) on overall survival (OS), treatment response and toxicity in patients with hepatocellular carcinoma (HCC) treated with sorafenib is unknown. We examined the impact of NAFLD on survival and toxicity in an international cohort of patie...
Autores principales: | Howell, Jessica, Samani, Amit, Mannan, Binish, Hajiev, Saur, Motedayen Aval, Leila, Abdelmalak, Rebecca, Tam, Vincent C., Bettinger, Dominik, Thimme, Robert, Taddei, Tamar H., Kaplan, David E., Seidensticker, Max, Sharma, Rohini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527996/ https://www.ncbi.nlm.nih.gov/pubmed/36199289 http://dx.doi.org/10.1177/17562848221100106 |
Ejemplares similares
-
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020) -
Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021) -
Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021) -
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020) -
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study
por: Kaplan, David E., et al.
Publicado: (2018)